Acquisition of Proteolix (Details) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2010	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010	Nov. 30, 2009	Jan. 31, 2011
Business Acquisition, Contingent Consideration [Line Items]
Potential contingent consideration payment		$ 535,000,000	$ 40,000,000	$ 535,000,000	$ 40,000,000
Contingent consideration expense		5,755,000	92,037,000	17,250,000	95,485,000
Acquisition of Proteolix (Textuals) [Abstract]
Cash consideration paid for acquisition of Proteolix						276,000,000
Contingent consideration payment	40,000,000
Portion of contingent consideration payment held in escrow account	4,000,000
Amount of cash consideration paid for acquisition of Proteolix held in escrow account						27,600,000
Goodwill						193,700,000
Goodwill impairment				0
Reduction in the payment paid within six month of original date							130,000,000
Reduction in the payment paid within twelve month of original date							80,000,000
Fair value of contingent consideration liability at acquisition date						199,000,000
Fair value of non-current contingent consideration liability at acquisition date	159,000,000
Percentage of cash consideration paid for Proteolix acquisition and contingent consideration payment held in an escrow account						10.00%
First installment [Member] | Accelerated Marketing Approval in United States For Relapsed Or Refractory Multiple Myeloma [Member]
Business Acquisition, Contingent Consideration [Line Items]
Potential contingent consideration payment						170,000,000
2nd installment [Member] | Marketing Approval In European Union For Relapsed Or Refractory Multiple Myeloma [Member]
Business Acquisition, Contingent Consideration [Line Items]
Potential contingent consideration payment							65,000,000
3rd installment [Member] | Marketing Approval In United States For Relapsed Multiple Myeloma [Member]
Business Acquisition, Contingent Consideration [Line Items]
Potential contingent consideration payment							150,000,000
Fourth installment [Member] | Marketing Approval For Relapsed Multiple Myeloma In European Union [Member]
Business Acquisition, Contingent Consideration [Line Items]
Potential contingent consideration payment							150,000,000
Escrow Account Liability (Member)
Business Acquisition, Contingent Consideration [Line Items]
Cash consideration paid for Proteolix acquisition and contingent consideration payment held in an escrow account	10.00%					10.00%
PTRS [Member]
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration expense		5,755,000	92,037,000	17,250,000	95,485,000
Maximum [Member]
Business Acquisition, Contingent Consideration [Line Items]
Potential contingent consideration payment						535,000,000
Minimum [Member]
Business Acquisition, Contingent Consideration [Line Items]
Potential contingent consideration payment						$ 0